Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'd wait for some positive news before selling if I was here for the short term. Directors bought in at 50p iirc ............. selling now would be less then prudent IMO.
decent sell indicator?
piohc1... good stuff. Onwards and upwards.
Britishbulls issue BUY signal
At the grave risk of being accused to ramp up the share, I'd say we can do a lot better than 60+ ... time will tell ;-))
Just hold and see where this one goes... lacks the mass hysteria of other stocks.... but have a diversified pipeline of opportunities. So not a rainbow type chasing COVID stock. 60+ in due course.
No problem Manager.
Edit to my last message, where I wrote consideration it should have read as consolidation (autocorrect).
I'm in here at 59p average so you're doing better than me too :D
Honestly I'm just in DDDD for a mid term trade.
I'll be looking to use profits here to top up my long term holding Oxford Metrics Ticker(OMG).
Hopefully sooner rather than latter as it's in a dip too!
Thank You Michael, I bought this share @ 46p sold a nice bit @ 54p, The bought more back again which gave me spot on 56p, your right about Pharma shares, I bought Tizannia @ 53p sold @ 95p, Yes great you say, but there is not enough room here to write some of the losses i have had in the early days jumping from share to share to earn a quick buck, This share dealing is certainly an eye opener, but thank you so much for your help and comments....
Looking good Manager511
Ready to break back into the 60's again.
Thank you Spin, I read so much on here about shares are good ,next post they are bad, i think sometimes the people post on here don't own any shares at all and just want to put down the people that have, i am fairly new to this but have done quite well so far with gut instincts, but sometimes its nice to hear from someone who knows a bit about it to help you, lets hope they soar and we can have a drink on them..... thank you again.
At 56p your average is a little lower than mine! DDDD has now become one of my most significant investment even though it's a relatively recent discovery. So that in itself gives you an answer though it's a subjective one ;-)
Agree that the share price now bears little relevance to the fair value whatever that is. However, nothing is in the bag and each individual project - in isolation - may have a higher probability of failure than success. That would be normal. Having said that, the beauty here - and among other DDDD strong points - is that there are a number of opportunities which makes at least one major success - even in the short to medium time horizon - quite likely. Also, at the current share price the reward to risk ratio seems very attractive.
If one looks at the overall picture as a number of new (perceived) opportunities have sprung up in the wake of the coronavirus crisis: a finite pool of funds has been chasing numerous moving targets in the life science sector but also elsewhere as other sectors are now regaining strength having been hit by the coronavirus crisis. Hence, the volatility which is probably also the reason that this share presents us with an opportunity in the case of DDDD...but my guess is that the share price will recover quickly especially if a trigger arrives in the form of positive news.
I believe what you are seeing here is a lot of derisking and consideration following the lows of march/April and recent 80p high. This really just needs a spark to ignite. Good news is sure to come and you'll be sat on secure profits, I am in no doubt.
Do you think these shares are going up in the near future, I am in large for me @ 56p ,
You're welcome Spin. As you said yesterday, the share has been oversold. Let's assume the sellers are through, as we no longer get shareholding related RNSs and their remaining stakes have been reduced to low levels anyway.
In that case, we can look forward to an upward trend of the share price in anticipation of exciting developments this year. Let's not forget that even one "goal" would suffice to give a major uplift in the company's value... and we are having "multiple shots". That's setting aside the possibility of more than one goal ... :-))
Much appreciated Michael, good man!
Here is the response (see below) I got yesterday from the company. Impressive turnaround time from them. Hoping to encourage eventually an RNS as in one-to-one reply they can only restate information previously released. Nonetheless good to know covid-19 is on track and also that the vaccine collaboration agreement with Merck is alive and kicking "as planned": useful to know as 8 months have almost passed since the announcement in early October 2019. Might we see an unexpected announcement in the short-term?
"Thanks for your enquiry. I have address each of your queries below.
1. Work is ongoing to get the Phase II COVID-19 study up and running as quickly as possible. At this time we are unable to provide specific updates beyond what is already in the public domain, however we are on track for a Q2 2020 start as stated in the Management Presentation available in the Reports & Presentations area of our website. When we have updates on the study's progress, rest assured we will make these available in a timely manner, through Company announcements and the study’s entry on clinicaltrials.gov. Please be advised that dates on clinicaltrials.gov are provisional estimates only and may be subject to change.
2. I presume you are referring to our research collaboration with MSD in the vaccines space, as opposed to our oncology clinical collaboration combining 4D’s MRx0518 with MSD’s Keytruda. The multi-year research collaboration is subject to strict confidentiality agreements with MSD, so at this moment we are unfortunately unable to provide updates other than the programme is continuing as planned.
3. 4D is in the business of clinical development of novel therapeutics, which as I’m sure you appreciate takes time. I would like to direct your attention to our pipeline (available on our website) and again to slide 27 of the Management Presentation on our website, which lays out multiple upcoming clinical catalysts across multiple programmes in different therapeutic areas in the coming year. Further, I would like to highlight the recently reported positive updates on two of our key lead programmes, Blautix® for IBS and MRx0518 in immuno-oncology, in roughly the last month.
4. Under AIM regulations 4D is required to update the Major Shareholders listing on its website twice yearly. We receive analyses quarterly and update the table accordingly.
I hope I have been able to address some of your concerns, and would reiterate the numerous catalysts for 4D and our shareholders coming up in the near-to-mid-term.
Thank you for your continued interest and support of 4D pharma. "
Regards,
Investor Relations, 4D pharma plc "
Sent the letter below to the company earlier today and posting it here as the issues raised may be of interest to other investors. In the meantime, pleased to see that the share price is bouncing back today.
"Dear 4D Pharma team,
Thanks for all your hard endeavours.
Can I suggest that the timing would be right for the company to issue an update with specificand progress related information regarding the various projects? In addition, more than six months since the collaboration with Merck was announced, could now be the right time to shed some more light as to what may be expected of such agreement?
More specifically:
1. what is the status of the MRx4DP0004 trials? The following link has not been updated since 27th April and states start of the study in May.
https://clinicaltrials.gov/ct2/show/NCT04363372?term=NCT04363372&draw=2&rank=1
Also, given that the more than one month has lapsed since the RNS informing investors about its fast tracking, an update has been due for some time.
2. Could some more light be shed as to what we can expect in 2020 of the agreement with Merck? For example, are they to pick one or more drug/therapy candidates from the MRx platform for joint development? It was reported in the press yesterday that they teamed up with a biotherapeutics company with respect to the development of an antiviral candidate in order to achieve covid-19 treatment. Has the possibility of teaming up with respect to MRx4DP0004 been raised?
3. The RNS of 26th May reinforced the impression that many positive things are going on behind the scenes, but you'd probably agree that it was quite general. Frankly, it may have contributed to the significant share price fall of around 15%. Being more specific and substantiating a little more the path to the "multiple shots at goal" swould help investors get a better understanding of what's to come and a clearer sense of direction. Otherwise, justice is not be done to the excellent efforts under way.
4. Finally, can I bring to your attention that the main shareholders table has not been updated for some time?
Kind regards and thank you in advance for your response"